Should HGF- or MET-directed therapy prove to be an effective treatment option for patients with GEC, experience with other RTK inhibitors suggests that resistance will invariably develop even in the subset of cancers that initially derive clinical benefit [85]. The gene discussed is HGF; the disease is cancer.